BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 1505076)

  • 1. Minocycline in combination with chemotherapy or radiation therapy in vitro and in vivo.
    Sotomayor EA; Teicher BA; Schwartz GN; Holden SA; Menon K; Herman TS; Frei E
    Cancer Chemother Pharmacol; 1992; 30(5):377-84. PubMed ID: 1505076
    [TBL] [Abstract][Full Text] [Related]  

  • 2. beta-cyclodextrin tetradecasulfate/tetrahydrocortisol +/- minocycline as modulators of cancer therapies in vitro and in vivo against primary and metastatic Lewis lung carcinoma.
    Teicher BA; Sotomayor EA; Huang ZD; Ara G; Holden S; Khandekar V; Chen YN
    Cancer Chemother Pharmacol; 1993; 33(3):229-38. PubMed ID: 8269604
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Modulation of alkylating agents by etanidazole and Fluosol-DA/carbogen in the FSaIIC fibrosarcoma and EMT6 mammary carcinoma.
    Teicher BA; Herman TS; Tanaka J; Eder JP; Holden SA; Bubley G; Coleman CN; Frei E
    Cancer Res; 1991 Feb; 51(4):1086-91. PubMed ID: 1825474
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Response of the FSaII fibrosarcoma to antiangiogenic modulators plus cytotoxic agents.
    Teicher BA; Holden SA; Ara G; Northey D
    Anticancer Res; 1993; 13(6A):2101-6. PubMed ID: 7507654
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combination of etanidazole with cyclophosphamide and platinum complexes.
    Teicher BA; Herman TS; Shulman L; Bubley G; Coleman CN; Frei E
    Cancer Chemother Pharmacol; 1991; 28(3):153-8. PubMed ID: 1830248
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vivo modulation of several anticancer agents by beta-carotene.
    Teicher BA; Schwartz JL; Holden SA; Ara G; Northey D
    Cancer Chemother Pharmacol; 1994; 34(3):235-41. PubMed ID: 8004757
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CAI: effects on cytotoxic therapies in vitro and in vivo.
    Teicher BA; Holden SA; Chen YN; Ara G; Korbut TT; Northey D
    Cancer Chemother Pharmacol; 1994; 34(6):515-21. PubMed ID: 7923563
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of pentoxifylline as a modulator of alkylating agent activity in vitro and in vivo.
    Teicher BA; Holden SA; Herman TS; Epelbaum R; Pardee AB; Dezube B
    Anticancer Res; 1991; 11(4):1555-60. PubMed ID: 1746913
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Minocycline as a modulator of chemotherapy and hyperthermia in vitro and in vivo.
    Teicher BA; Holden SA; Liu CJ; Ara G; Herman TS
    Cancer Lett; 1994 Jul; 82(1):17-25. PubMed ID: 8033065
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antiangiogenic agents potentiate cytotoxic cancer therapies against primary and metastatic disease.
    Teicher BA; Sotomayor EA; Huang ZD
    Cancer Res; 1992 Dec; 52(23):6702-4. PubMed ID: 1384969
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Modulation of alkylating agents by lonidamine in vivo.
    Teicher BA; Holden SA; Herman TS; Frei E
    Semin Oncol; 1991 Apr; 18(2 Suppl 4):7-10. PubMed ID: 1903216
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Etoposide with lonidamine or pentoxifylline as modulators of alkylating agent activity in vivo.
    Tanaka J; Teicher BA; Herman TS; Holden SA; Dezube B; Frei E
    Int J Cancer; 1991 Jun; 48(4):631-7. PubMed ID: 2045206
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interaction of SR-4233 with hyperthermia and radiation in the FSaIIC murine fibrosarcoma tumor system in vitro and in vivo.
    Herman TS; Teicher BA; Coleman CN
    Cancer Res; 1990 Aug; 50(16):5055-9. PubMed ID: 2379171
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interaction of D,L- and D-tetraplatin with hyperthermia in vitro and in vivo.
    Epelbaum R; Teicher BA; Holden SA; Ara G; Varshney A; Herman TS
    Eur J Cancer; 1992; 28A(4-5):794-800. PubMed ID: 1524897
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enhancement of alkylating agent activity by SR-4233 in the FSaIIC murine fibrosarcoma.
    Holden SA; Teicher BA; Ara G; Herman TS; Coleman CN
    J Natl Cancer Inst; 1992 Feb; 84(3):187-93. PubMed ID: 1542129
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combination of N,N',N"-triethylenethiophosphoramide and cyclophosphamide in vitro and in vivo.
    Teicher BA; Holden SA; Cucchi CA; Cathcart KN; Korbut TT; Flatow JL; Frei E
    Cancer Res; 1988 Jan; 48(1):94-100. PubMed ID: 3121169
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A new concentrated perfluorochemical emulsion and carbogen breathing as an adjuvant to treatment with antitumor alkylating agents.
    Teicher BA; Holden SA; Ara G; Ha CS; Herman TS; Northey D
    J Cancer Res Clin Oncol; 1992; 118(7):509-14. PubMed ID: 1624542
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Potentiation of cytotoxic therapies by TNP-470 and minocycline in mice bearing EMT-6 mammary carcinoma.
    Teicher BA; Holden SA; Dupuis NP; Kakeji Y; Ikebe M; Emi Y; Goff D
    Breast Cancer Res Treat; 1995; 36(2):227-36. PubMed ID: 8534870
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Paclitaxel/carboplatin administration along with antiangiogenic therapy in non-small-cell lung and breast carcinoma models.
    Herbst RS; Takeuchi H; Teicher BA
    Cancer Chemother Pharmacol; 1998; 41(6):497-504. PubMed ID: 9554595
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Classification of antineoplastic treatments by their differential toxicity toward putative oxygenated and hypoxic tumor subpopulations in vivo in the FSaIIC murine fibrosarcoma.
    Teicher BA; Holden SA; al-Achi A; Herman TS
    Cancer Res; 1990 Jun; 50(11):3339-44. PubMed ID: 2334928
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.